Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations?
✍ Scribed by U. Musabak; S. Pay; H. Erdem; I. Simsek; A. Pekel; A. Dinc; A. Sengul
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 237 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0172-8172
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background Behçet's syndrome is a systemic, relapsing immuno-inflammatory disease with a generalized vasculitis of the microvasculature endothelial dysfunction. Leptin, a recently discovered neuroendocrine hormone, is a metabolic peptide that appears to be involved. Serum proinflammatory cytokines u
## Abstract **Background/aims** Vascular endothelial growth factor (VEGF) is a cytokine participating in inflammation with potent endothelial cell effects. It is produced by macrophages, neutrophils and vascular endothelial cells and can alter vessel permeability. Behçet's syndrome is a systemic in
BACKGROUND. Several investigators have revealed that urokinase-type plasminogen activator (uPA) and its receptor (uPAR) are overexpressed in serum as well as in tumor tissues in patients with various types of cancer. In this study, we examined whether the serum levels of uPA and uPAR could be used a